John R Silber
Overview
Explore the profile of John R Silber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1217
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang K, Kievit F, Chiarelli P, Stephen Z, Lin G, Silber J, et al.
Adv Funct Mater
. 2021 Mar;
31(6).
PMID: 33708035
Temozolomide (TMZ) is the standard of care chemotherapy drug for treating glioblastomas (GBMs), the most aggressive cancer that affects people of all ages. However, its therapeutic efficacy is limited by...
2.
Pattwell S, Arora S, Cimino P, Ozawa T, Szulzewsky F, Hoellerbauer P, et al.
Nat Commun
. 2020 Jun;
11(1):2977.
PMID: 32532995
Independent scientific achievements have led to the discovery of aberrant splicing patterns in oncogenesis, while more recent advances have uncovered novel gene fusions involving neurotrophic tyrosine receptor kinases (NTRKs) in...
3.
Kievit F, Wang K, Ozawa T, Tarudji A, Silber J, Holland E, et al.
Nanomedicine
. 2017 Jun;
13(7):2131-2139.
PMID: 28614736
Glioblastoma (GBM) remains incurable, and recurrent tumors rarely respond to standard-of-care radiation and chemo-therapies. Therefore, strategies that enhance the effects of these therapies should provide significant benefits to GBM patients....
4.
Stephen Z, Gebhart R, Jeon M, Blair A, Ellenbogen R, Silber J, et al.
Bioconjug Chem
. 2016 Dec;
28(1):194-202.
PMID: 27936607
Nanoparticle-mediated delivery of chemotherapeutics has demonstrated potential in improving anticancer efficacy by increasing serum half-life and providing tissue specificity and controlled drug release to improve biodistribution of hydrophobic chemotherapeutics. However,...
5.
Wang K, Kievit F, Erickson A, Silber J, Ellenbogen R, Zhang M
Adv Healthc Mater
. 2016 Nov;
5(24):3173-3181.
PMID: 27805789
The lack of in vitro models that support the growth of glioblastoma (GBM) stem cells (GSCs) that underlie clinical aggressiveness hinders developing new, effective therapies for GBM. While orthotopic patient-derived...
6.
Bonow R, Silber J, Enzmann D, Beauchamp N, Ellenbogen R, Mourad P
J Ther Ultrasound
. 2016 Mar;
4:6.
PMID: 26929821
Cerebral vasospasm is a major cause of morbidity and mortality in patients with subarachnoid hemorrhage (SAH), causing delayed neurological deficits in as many as one third of cases. Existing therapy...
7.
Wang K, Kievit F, Jeon M, Silber J, Ellenbogen R, Zhang M
Adv Healthc Mater
. 2015 Oct;
4(17):2719-26.
PMID: 26498165
Human tumor necrosis factor α-related apoptosis-inducing ligand (TRAIL) is an attractive cancer therapeutic because of its ability to induce apoptosis in tumor cells while having a negligible effect on normal...
8.
Kievit F, Stephen Z, Wang K, Dayringer C, Sham J, Ellenbogen R, et al.
Mol Oncol
. 2015 Feb;
9(6):1071-80.
PMID: 25681012
Medulloblastoma (MB) and ependymoma (EP) are the most common pediatric brain tumors, afflicting 3000 children annually. Radiotherapy (RT) is an integral component in the treatment of these tumors; however, the...
9.
Kumar A, Boyle E, Tokita M, Mikheev A, Sanger M, Girard E, et al.
Genome Biol
. 2015 Jan;
15(12):530.
PMID: 25608559
Background: The extent of intratumoral mutational heterogeneity remains unclear in gliomas, the most common primary brain tumors, especially with respect to point mutation. To address this, we applied single molecule...
10.
Bobola M, Alnoor M, Chen J, Kolstoe D, Silbergeld D, Rostomily R, et al.
BBA Clin
. 2015 Jan;
3:1-10.
PMID: 25558448
Background: CpG methylation in the O-methylguanine-DNA methyltransferase (MGMT) promoter is associated with better outcome following alkylating agent chemotherapy in glioblastoma (GBM) and anaplastic glioma (AG). To what extent improved response...